Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol

Pharmacogenetics and Genomics

Volumn 21, Issue 4, 2011, Pages 206-216

  Giegling, Ina ^a   Drago, Antonio ^c   Dolžan, Vita ^e   Plesničar, Blanka Kores ^f   Schäfer, Martin ^a   Hartmann, Annette M ^a   Sander, Thomas ^b   Toliat, Mohammad Reza ^b   Möller, Hans Jürgen ^a   Stassen, Hans H ^d   Rujescu, Dan ^a   Serretti, Alessandro ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

^f Psychiatric Clinic Ljubljana   (Slovenia)

Author keywords

Antipsychotic; Gene; Glutamatergic; Pharmacogenetics; Schizophrenia

Indexed keywords

GLUTAMATE RECEPTOR; GLYCINE TRANSPORTER 2; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROTEIN GAD1; PROTEIN GRIA1; PROTEIN GRIA3; PROTEIN GRIA4; PROTEIN GRID2; PROTEIN GRIK1; PROTEIN GRIK2; PROTEIN GRIK3; PROTEIN GRIK4; PROTEIN GRIM1; PROTEIN GRIM4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE REPLICATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79955483855     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833efb18     Document Type: Article

References (63)

1. Lynch MR. Schizophrenia and the D1 receptor: focus on negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:797-832.
2. van Berckel BN, Kegeles LS, Waterhouse R, Guo N, Hwang DR, Huang Y, et al. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 2006; 31:967-977.
3. Maeda J, Suhara T, Okauchi T, Semba J. Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex. Neurosci Lett 2003; 336:171-174. (Pubitemid 36044605)
4. Jin S, Fredholm BB. Role of NMDA, AMPA and kainate receptors in mediating glutamate- and 4-AP-induced dopamine and acetylcholine release from rat striatal slices. Neuropharmacology 1994; 33:1039-1048. (Pubitemid 24306627)
5. Creese I, Burt DR, Synder SH. The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. Life Sci 1975; 17:1715-1719.
6. Janowsky DS, el-Yousel MK, Davis JM, Sekerke HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973; 28:185-191.
7. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987; 91:415-433. (Pubitemid 17038204)
8. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261:717-719.
9. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56:29-36. (Pubitemid 29055047)
10. Murray JB. Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol 2002; 136:319-327.
11. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214. (Pubitemid 24081509)
12. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17:141-150. (Pubitemid 27365955)
13. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14:301-307. (Pubitemid 26151927)
14. Bourgeois JP, Goldman-Rakic PS, Rakic P. Synaptogenesis in the prefrontal cortex of rhesus monkeys. Cereb Cortex 1994; 4:78-96. (Pubitemid 24066074)
15. Ikonomidou C, Mosinger JL, Salles KS, Labruyere J, Olney JW. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J Neurosci 1989; 9:2809-2818. (Pubitemid 19214314)
16. Feinberg I. Cortical pruning and the development of schizophrenia. Schizophr Bull 1990; 16:567-570.
17. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005; 10:434-449. (Pubitemid 40646432)
18. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992; 49:195-205.
19. Humphries C, Mortimer A, Hirsch S, de Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 1996; 7:2051-2055. (Pubitemid 26348223)
20. Conklin HM, Curtis CE, Katsanis J, Iacono WG. Verbal working memory impairment in schizophrenia patients and their first-degree relatives: evidence from the digit span task. Am J Psychiatry 2000; 157:275-277. (Pubitemid 30080912)
21. Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG Jr. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry 1993; 33:513-519. (Pubitemid 23167217)
22. Paulman RG, Devous MD Sr, Gregory RR, Herman JH, Jennings L, Bonte FJ, et al. Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function. Biol Psychiatry 1990; 27:377-399. (Pubitemid 20083767)
23. Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci U S A 2007; 104:14843-14848. (Pubitemid 350003230)
24. Brene S, Messer C, Nestler EJ. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: regulation by haloperidol. Neuroscience 1998; 84:813-823. (Pubitemid 28137897)
25. McCoy L, Cox C, Richfield EK. Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse 1998; 28:195-207. (Pubitemid 28086834)
26. Toyoda H, Takahata R, Inayama Y, Sakai J, Matsumura H, Yoneda H, et al. Effect of antipsychotic drugs on the gene expression of NMDA receptor subunits in rats. Neurochem Res 1997; 22:249-252. (Pubitemid 27091811)
27. Scarr E, Parkin FM, Pavey G, Dean B. Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats. Life Sci 2002; 70:2699-2705. (Pubitemid 34310562)
28. Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 1995; 15:2453-2461.
29. Konieczny J, Ossowska K, Wolfarth S, Pilc A. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedebergs Arch Pharmacol 1998; 358:500-502. (Pubitemid 28470849)
30. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 2008; 74:1345-1358.
31. Ossowska K, Konieczny J, Wolfarth S, Pilc A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 2005; 49:447-455. (Pubitemid 41169969)
32. Chen AC, Gurling HM. D2 dopamine receptor but not AMPA and kainate glutamate receptor genes show altered expression in response to long term treatment with trans- and cis-flupenthixol in the rat brain. Brain Res Mol Brain Res 1999; 68:14-21. (Pubitemid 29243990)
33. Sokolov BP. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J Neurochem 1998; 71:2454-2464. (Pubitemid 28531256)
34. Toyooka K, Iritani S, Makifuchi T, Shirakawa O, Kitamura N, Maeda K, et al. Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 2002; 83:797-806. (Pubitemid 35316029)
35. O'Connor JA, Muly EC, Arnold SE, Hemby SE. AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs. Schizophr Res 2007; 90:28-40. (Pubitemid 46177560)
36. Meador-Woodruff JH, King RE, Damask SP, Bovenkerk KA. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine. Mol Psychiatry 1996; 1:41-53. (Pubitemid 126442394)
37. Wang X, Zhong P, Gu Z, Yan Z. Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J Neurosci 2003; 23:9852-9861. (Pubitemid 37371599)
38. Fumagalli F, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C, et al. Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. J Neurosci Res 2003; 72:622-628. (Pubitemid 36578648)
39. Di Forti M, Lappin JM, Murray RM. Risk factors for schizophrenia-all roads lead to dopamine. Eur Neuropsychopharmacol 2007; 17 (Suppl 2):S101-S107.
40. De Bartolomeis A, Aloj L, Ambesi-Impiombato A, Bravi D, Caraco C, Muscettola G, Barone P. Acute administration of antipsychotics modulates Homer striatal gene expression differentially. Brain Res Mol Brain Res 2002; 98:124-129. (Pubitemid 34142286)
41. Gardoni F, Frasca A, Zianni E, Riva MA, Di Luca M, Fumagalli F. Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor composition in rat striatum. Eur Neuropsychopharmacol 2008; 18:531-534. (Pubitemid 351726429)
42. Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A, et al. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 2001; 50:117-122. (Pubitemid 32728211)
43. Chartoff EH, Ward RP, Dorsa DM. Role of adenosine and N-methyl-Daspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther 1999; 291:531-537. (Pubitemid 29503521)
44. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 2003; 1003:138-158. (Pubitemid 38083052)
45. Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009; 17:946-957.
46. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009; 14:804-819.
47. Tsai HT, Caroff SN, Miller del D, McEvoy J, Lieberman JA, North KE, et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:336-340.
48. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, et al. Candidate-gene association analysis of response to risperidone in African- American and white patients with schizophrenia. Pharmacogenomics J 2009; 9:311-318.
49. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460:748-752.
50. Kastelic M, Koprivsek J, Plesnicar BK, Serretti A, Mandelli L, Locatelli I, et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:387-392.
51. Plesnicar BK, Zalar B, Breskvar K, Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 2006; 20:829-833. (Pubitemid 44622748)
52. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. Am J Ophthalmol 2000; 130:688.
53. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 1998; 2:1-124. i-iv.
54. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-1892. (Pubitemid 30419054)
55. Greene T. Randomized and observational studies in nephrology: how strong is the evidence? Am J Kidney Dis 2009; 53:377-388.
56. Giegling I, Drago A, Schafer M, Moller HJ, Rujescu D, Serretti A. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2010; 44:487-492.
57. Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1562-1566.
58. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663-667. (Pubitemid 36750143)
59. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24:192-208. (Pubitemid 38380844)
60. Livak KJ. Allelic discrimination using fluorogenic probes and the 50 nuclease assay. Genet Anal 1999; 14:143-149. (Pubitemid 29095371)
61. Ronaghi M. Pyrosequencing for SNP genotyping. Methods Mol Biol 2003; 212:189-195.
62. Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev 2007; 56:283-321. (Pubitemid 350176598)
63. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74:765-769. (Pubitemid 38420107)